44,637 Shares in Roivant Sciences Ltd. (NASDAQ:ROIV) Acquired by SG Americas Securities LLC

SG Americas Securities LLC acquired a new position in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 44,637 shares of the company's stock, valued at approximately $472,000.

Other large investors have also recently bought and sold shares of the company. Allspring Global Investments Holdings LLC grew its position in shares of Roivant Sciences by 42.6% during the fourth quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company's stock worth $60,000 after acquiring an additional 1,608 shares during the last quarter. Headlands Technologies LLC bought a new position in Roivant Sciences in the 4th quarter worth about $36,000. DNB Asset Management AS increased its stake in shares of Roivant Sciences by 6.4% in the second quarter. DNB Asset Management AS now owns 56,022 shares of the company's stock valued at $592,000 after purchasing an additional 3,386 shares during the period. Vanguard Personalized Indexing Management LLC raised its holdings in shares of Roivant Sciences by 26.7% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 18,742 shares of the company's stock valued at $210,000 after buying an additional 3,955 shares during the last quarter. Finally, Dynamic Technology Lab Private Ltd boosted its position in shares of Roivant Sciences by 35.1% during the fourth quarter. Dynamic Technology Lab Private Ltd now owns 17,155 shares of the company's stock worth $193,000 after buying an additional 4,458 shares during the period. Institutional investors own 64.76% of the company's stock.

Analysts Set New Price Targets

Several analysts have weighed in on the company. Piper Sandler lifted their target price on Roivant Sciences from $20.00 to $22.00 and gave the company an "overweight" rating in a research note on Wednesday, July 10th. Cantor Fitzgerald reaffirmed an "overweight" rating on shares of Roivant Sciences in a report on Tuesday, June 18th. Finally, HC Wainwright reaffirmed a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a research note on Monday. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $17.10.

Roivant Sciences Trading Up 2.7 %

Shares of NASDAQ ROIV traded up $0.31 during mid-day trading on Wednesday, hitting $11.79. 5,240,520 shares of the company traded hands, compared to its average volume of 5,753,846. The company has a quick ratio of 25.24, a current ratio of 25.24 and a debt-to-equity ratio of 0.07. Roivant Sciences Ltd. has a 1 year low of $8.24 and a 1 year high of $13.24. The stock has a market capitalization of $8.71 billion, a price-to-earnings ratio of 2.33 and a beta of 1.24. The business has a 50 day moving average of $10.91 and a two-hundred day moving average of $10.93.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings data on Thursday, August 8th. The company reported $0.12 EPS for the quarter, topping analysts' consensus estimates of ($0.21) by $0.33. Roivant Sciences had a net margin of 3,484.86% and a negative return on equity of 25.05%. The firm had revenue of $55.10 million during the quarter, compared to analyst estimates of $30.72 million. During the same quarter last year, the business posted ($0.38) EPS. The company's revenue was up 155.1% on a year-over-year basis. On average, sell-side analysts anticipate that Roivant Sciences Ltd. will post -1.12 earnings per share for the current fiscal year.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.